170
Participants
Start Date
May 31, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
July 31, 2023
Plasma soluble TNF receptor pulldown
The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
Plasma soluble TNF receptor pulldown + chemotherapy
"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
Chemotherapy Drugs, Cancer
Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
NOT_YET_RECRUITING
Altunizade Acıbadem Hospital, Istanbul
RECRUITING
Katedra i Klinika Onkologii UJ CM, Krakow
RECRUITING
Centrum Medyczne INTERCOR Sp. z o.o., Bydgoszcz
RECRUITING
Klinika Pneumonologii, Onkologii i Alergologii SPSK Nr 4 w Lublinie, Lublin
SUSPENDED
Centrum Medyczne Pratia Poznań, Skórzewo
Lead Sponsor
Immunicom Inc
INDUSTRY